The use of amelogenin protein in the treatment of hard-to-heal wounds.
The management of hard-to-heal or chronic wounds places a high economic burden on healthcare services. This problem is exacerbated by the increasing age of the general population, an increasing diabetes population and a high prevalence of such wounds in the elderly, patients with diabetes and those with venous insufficiency. Standard treatments for such wounds, such as compression therapy in venous leg ulcers, debridement and wound care for diabetic foot ulcers, can still leave a significant population with non-healing wounds, resulting in extended hospital stays and reduced quality of life. The use of amelogenin (Xelma, Mölnlycke Health Care) for the treatment of a variety of chronic wounds has been assessed in both case studies and larger clinical trials with encouraging findings. This article examines the findings of studies relating to amelogenin in the treatment of hard-to-heal wounds.
Chadwick
Paul
P
Salford PCT, Podiatry and Foot Health, Hope Hospital, Salford, UK.
Acton
Claire
C
D053523:Amelogenin / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D017719:Diabetic Foot / Q000150:complications / Q000517:prevention & control*; D005122:Exudates and Transudates; D006801:Humans; D009730:Nursing Assessment; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D017511:Pyoderma Gangrenosum / Q000517:prevention & control; D012307:Risk Factors; D017592:Skin Care / Q000379:methods / Q000451:nursing; D016896:Treatment Outcome; D014647:Varicose Ulcer / Q000150:complications / Q000517:prevention & control*; D014945:Wound Healing / Q000187:drug effects*
D053523:Amelogenin